Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Experimental Cell Research

• Publication date

  2007-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.YEXCR.2007.06.020PMID 17669398
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells

  2007cited by this paper
• IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells.

  2006cited by this paper
• Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.

  2006cited by this paper
• PPARγ-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma

  2006cited by this paper
• Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia

  2006cited by this paper
• Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues.

  2006cited by this paper
• 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside Inhibits Cancer Cell Proliferation in Vitro and in Vivo via AMP-activated Protein Kinase*

  2005cited by this paper
• AMPK, the metabolic syndrome and cancer.

  2005cited by this paper
• Cell responses to FGFR3 signalling: growth, differentiation and apoptosis.

  2005cited by this paper
• Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma

  2005cited by this paper
• Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry.

  2005cited by this paper
• Specific roles for the PI3K and the MEK–ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model

  2004cited by this paper
• The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.

  2004cited by this paper
• Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells.

  2004cited by this paper
• Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands.

  2004cited by this paper
• The AMP-activated protein kinase cascade--a unifying system for energy control.

  2004cited by this paper
• Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1.

  2004cited by this paper
• C75, a Fatty Acid Synthase Inhibitor, Reduces Food Intake via Hypothalamic AMP-activated Protein Kinase*

  2004cited by this paper
• Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

  2004cited by this paper
• AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms.

  2004cited by this paper
• Ligands of peroxisome proliferator-activated receptor &ggr; induce apoptosis in multiple myeloma

  2004cited by this paper
• Human multiple myeloma cells express peroxisome proliferator-activated receptor γ and undergo apoptosis upon exposure to PPARγ ligands

  2004cited by this paper
• A possible linkage between AMP‐activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway

  2003cited by this paper
• Downstream effectors of oncogenic ras in multiple myeloma cells.

  2003cited by this paper
• A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.

  2003cited by this paper
• Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.

  2003cited by this paper
• Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes.

  2003cited by this paper
• Map kinase signaling pathways and hematologic malignancies.

  2003cited by this paper
• RANK‐Fc in myeloma

  2002cited by this paper
• Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk.

  2002cited by this paper
• Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein.

  2002cited by this paper
• Effects of Stimulation of AMP-activated Protein Kinase on Insulin-like Growth Factor 1- and Epidermal Growth Factor-dependent Extracellular Signal-regulated Kinase Pathway*

  2001cited by this paper
• Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line.

  2001cited by this paper
• Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway.

  2000cited by this paper
• Insulin‐like growth factor induces the survival and proliferation of myeloma cells through an interleukin‐6‐independent transduction pathway

  2000cited by this paper
• The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.

  2000cited by this paper
• The 5′‐AMP‐activated protein kinase inhibits the transcriptional stimulation by glucose in liver cells, acting through the glucose response complex

  1998cited by this paper
• The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?

  1998cited by this paper
• Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes.

  1995cited by this paper
• N- and K-ras oncogenes in plasma cell dyscrasias.

  1994cited by this paper

• Metformin as antiviral therapy protects hyperglycemic and diabetic patients

  2025cites this paper
• Troglitazone as a Novel Nrf2 Activator to Attenuate Oxidative Stress and Exert Neuroprotection.

  2025cites this paper
• Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy

  2024cites this paper
• The prognostic significance of ubiquitination-related genes in multiple myeloma by bioinformatics analysis

  2024cites this paper
• Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan

  2023influential citation
• Far-Infrared Irradiation Decreases Proliferation in Basal and PDGF-Stimulated VSMCs Through AMPK-Mediated Inhibition of mTOR/p70S6K Signaling Axis

  2023cites this paper
• Metabolic Vulnerabilities in Multiple Myeloma

  2022cites this paper
• Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma

  2021cites this paper
• The Association between Metabolic Syndrome and Multiple Myeloma

  2020cites this paper
• Emerging protein kinase inhibitors for the treatment of multiple myeloma

  2019cites this paper
• Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma

  2018cites this paper
• Role of AMP-protein kinase (AMPK) in regulation of perivascular adipose tissue (PVAT) function

  2017cites this paper
• Desynchronization of Circadian Clocks in Cancer: A Metabolic and Epigenetic Connection

  2017cites this paper
• New synthetic AICAR derivatives with enhanced AMPK and ACC activation

  2016cites this paper
• Kinase inhibitors as potential agents in the treatment of multiple myeloma

  2016cites this paper
• Molecular mechanisms of apoptosis induction by AICAR and the new prohibitin-binding compound fluorizoline

  2015cites this paper
• Negative regulation of the LKB1/AMPK pathway by ERK in human acute myeloid leukemia cells.

  2015cites this paper
• 5-AMINOIMIDAZOL-4-KARBOKSIAMID-1-β-D-RIBOFURANOZID POTIČE NAKUPLJANJE LEUKEMIJSKIH STANICA U S-FAZI

  2015cites this paper
• LPS inhibits caspase 3-dependent apoptosis in RAW264.7 macrophages induced by the AMPK activator AICAR.

  2014cites this paper
• Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma

  2014cites this paper
• Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.

  2014cites this paper
• Metabolomics Identi fi es Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-b-Riboside-Induced Apoptosis in Multiple Myeloma Cells

  2013influential citation
• AICAR induces Bax/Bak-dependent apoptosis through upregulation of the BH3-only proteins Bim and Noxa in mouse embryonic fibroblasts

  2013cites this paper
• Aminoimidazole Carboxamide Ribonucleotide (AICAR) Inhibits the Growth of Retinoblastoma In Vivo by Decreasing Angiogenesis and Inducing Apoptosis

  2013cites this paper
• Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-β-Riboside-Induced Apoptosis in Multiple Myeloma Cells

  2013influential citation
• Models and discovery strategies for new therapies of retinoblastoma

  2013cites this paper
• Targeting LKB1 signaling in cancer.

  2013cites this paper
• Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

  2013cites this paper
• Targeting AMPK in the treatment of malignancies

  2012cites this paper
• Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study

  2012cites this paper
• Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies

  2012cites this paper
• Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma

  2012cites this paper
• LKB1/AMPK/mTOR signaling pathway in hematological malignancies: From metabolism to cancer cell biology

  2011cites this paper
• AMP kinase signals the insulin-like growth factor system whether adequate nutrient is present to support an anabolic response

  2011cites this paper
• Investigation of the intrinsic mechanism of drug resistance in multiple myeloma

  2011cites this paper
• AICAR inhibits cancer cell growth and triggers cell-type distinct effects on OXPHOS biogenesis, oxidative stress and Akt activation.

  2011cites this paper
• Bcr-Abl adds another twist to cell fate.

  2011cites this paper
• GATA2 finds its macrophage niche

  2011cites this paper
• Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.

  2011cites this paper
• Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP‐dependent kinase

  2010cites this paper
• OSU-03012 sensitizes TIB-196 myeloma cells to imatinib mesylate via AMP-activated protein kinase and STAT3 pathways.

  2010cites this paper
• Connecting the mechanisms of T‐cell regulation: dendritic cells as the missing link

  2010cites this paper
• AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies

  2010cites this paper
• Investigation of the effects of adenosine and purine nucleoside analogues on the viability of human breast cancer cells

  2010cites this paper
• Role of AMPK throughout meiotic maturation in the mouse oocyte: Evidence for promotion of polar body formation and suppression of premature activation

  2010cites this paper
• The role of the bone marrow microenvironment in the establishment and progression of multiple myeloma

  2010cites this paper
• Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells

  2009cites this paper
• Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001

  2009cites this paper
• Rôle du système IGF-1/insuline dans le Myélome Multiple

  2009cites this paper
• The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.

  2009cites this paper
• Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells

  2009cites this paper
• Overexpression of CYP2E1 induces HepG2 cells death by the AMP kinase activator 5′-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR)

  2009cites this paper
• Activation of AMPK inhibits inflammation in MRL/lpr mouse

  2009cites this paper
• The peptide‐semicarbazone S‐2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells

  2009cites this paper
• Differential regulation of AMP-activated kinase and AKT kinase in response to oxygen availability in crucian carp (Carassius carassius).

  2008cites this paper
• Mammalian target of rapamycin as a target in hematological malignancies.

  2008cites this paper
• Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model

  2008cites this paper
• Glucose sensing and the regulation of the AMP-activated protein kinase in yeast

  2008cites this paper
• Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5- Aminoimidazole-4-carboxamide-1-β-riboside (aicar) Induced Apoptosis in Multiple Myeloma Cells

  year unknowncites this paper
• In Addition, Other Cytokines 2646 8 S E P T E M B E R 2 0 1 1 I V O L U M E 1 1 8 , N U M B E R 1 0 Blood

  year unknowncites this paper